Keytruda Approved for Leading Form of Lung Cancer

October 2, 2015 9:00 PM

27 0

FRIDAY, Oct. 2, 2015 (HealthDay News) -- Keytruda (pembrolizumab) has been approved by the U.S. Food and Drug Administration to treat advanced cases of the most common type of lung malignancy, non-small cell lung cancer (NSCLC).

The drug is approved for people whose tumors produce a protein called PD-L1, and whose cancer has lingered despite use of other treatments, the agency said Friday in a news release.

Also read: FDA approves BioMarin rare metabolic disorder drug, shares rise

Read more

To category page